Skip to main content
SpringerLink
Log in

Pharmacological Interventions in Gambling Disorder

  • Chapter
  • First Online:
Gambling Disorder

Abstract

The current chapter covers pharmacological treatments for gambling disorder (GD). We discuss the role of opioid antagonists, glutaminergic drugs (NAC, memantine, topiramate), antidepressants, and other medications that have been investigated. Mechanisms of action and current evidence are examined.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Black DW, Moyer T, Schlosser S. Quality of life and family history in pathological gambling. J Nerv Ment Dis. 2003;191(2):124–6.

    PubMed  Google Scholar 

  2. Grant JE, Kim SW. Quality of life in kleptomania and pathological gambling. Compr Psychiatry. 2005;46(1):34–7.

    Article  Google Scholar 

  3. Petry NM, Stinson FS, Grant BF. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the national epidemiologic survey on alcohol and related conditions [CME]. J Clin Psychiatry. 2005;66(5):564–74.

    Article  Google Scholar 

  4. Pallesen S, Mitsem M, Kvale G, Johnsen BH, Molde H. Outcome of psychological treatments of pathological gambling: a review and meta-analysis. Addiction. 2005;100(10):1412–22.

    Article  Google Scholar 

  5. Petry NM, Ammerman Y, Bohl J, Doersch A, Gay H, Kadden R, et al. Cognitive-behavioral therapy for pathological gamblers. J Consult Clin Psychol. 2006;74(3):555.

    Article  Google Scholar 

  6. Lupi M, Martinotti G, Acciavatti T, Pettorruso M, Brunetti M, Santacroce R, et al. Pharmacological treatments in gambling disorder: a qualitative review. Biomed Res Int. 2014;2014:537306.

    Article  Google Scholar 

  7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub. 2013.

    Google Scholar 

  8. Blanco C, Moreyra P, Nunes EV, Saiz-Ruiz J, Ibanez A. Pathological gambling: addiction or compulsion? Semin Clin Neuropsychiatry. 2001;6(3):167–76.

    Article  CAS  Google Scholar 

  9. Potenza MN. The neurobiology of pathological gambling. Semin Clin Neuropsychiatry. 2001;6(3):217–26.

    Article  CAS  Google Scholar 

  10. Yip SW, Potenza MN. Treatment of gambling disorders. Curr Treat Options Psychiatry. 2014;1(2):189–203.

    Article  Google Scholar 

  11. Kim SW. Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry. 1998;59(4):159–64.

    Article  CAS  Google Scholar 

  12. Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci. 2009;10(8):561–72.

    Article  CAS  Google Scholar 

  13. Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol. 2001;16(5):285–9.

    Article  CAS  Google Scholar 

  14. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49(11):914–21.

    Article  CAS  Google Scholar 

  15. Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, Kallio A. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163(2):303–12.

    Article  Google Scholar 

  16. Grant JE, Kim SW, Hollander E, Potenza MN. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology. 2008;200(4):521–7.

    Article  CAS  Google Scholar 

  17. Toneatto T, Brands B, Selby P. A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling. Am J Addict. 2009;18(3):219–25.

    Google Scholar 

  18. Grant JE, Chamberlain SR, Odlaug BL, Potenza MN, Kim SW. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology. 2010;212(4):603–12.

    Article  CAS  Google Scholar 

  19. Kovanen L, Basnet S, Castren S, Pankakoski M, Saarikoski ST, Partonen T, Alho H, Lahti T. A randomised, double-blind, placebo-controlled trial of as-needed naltrexone in the treatment of pathological gambling. Eur Addict Res. 2016;22(2):70–9.

    Google Scholar 

  20. Asevedo E, Mendes AC, Berk M, Brietzke E. Systematic review of N-acetylcysteine in the treatment of addictions. Rev Bras Psiquiatr. 2014;36(2):168–75.

    Article  Google Scholar 

  21. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007;62(6):652–7.

    Article  CAS  Google Scholar 

  22. Evans SM, Levin FR, Brooks DJ, Garawi F. A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res. 2007;31(5):775–82.

    Article  CAS  Google Scholar 

  23. Arbaizar B, Gómez-Acebo I, Llorca J. Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. Gen Hosp Psychiatry. 2008;30(5):471–5.

    Article  Google Scholar 

  24. Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry. 2010;71(5):634–48.

    Article  CAS  Google Scholar 

  25. Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, McElroy SL, et al. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World J Biol Psychiatry. 2013;14(2):121–8.

    Article  Google Scholar 

  26. de Brito AMC, de Almeida Pinto MG, Bronstein G, Carneiro E, Faertes D, Fukugawa V, et al. Topiramate combined with cognitive restructuring for the treatment of gambling disorder: a two-center, randomized, double-blind clinical trial. J Gambl Stud. 2016;33(1):249–63.

    Article  Google Scholar 

  27. Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68(3):400–4.

    Article  Google Scholar 

  28. Grant JE, Potenza MN. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol. 2006;21(4):203–9.

    Article  Google Scholar 

  29. Gandara JJ, Sanz O, Gilaberte I. Fluoxetine: open-trial in pathological gambling. In Annual meeting of the American Psychiatric Association. 1999. p. 16–21.

    Google Scholar 

  30. Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry. 2002;63(1):44–8.

    Article  Google Scholar 

  31. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2014;(1):CD000031.

    Google Scholar 

  32. Moriyama TS, Polanczyk GV, Terzi FS, Faria KM, Rohde LA. Psychopharmacology and psychotherapy for the treatment of adults with ADHD—a systematic review of available meta-analyses. CNS Spectr. 2013;18(06):296–306.

    Article  Google Scholar 

  33. Black DW. An open-label trial of bupropion in the treatment of pathologic gambling. J Clin Psychopharmacol. 2004;24(1):108–11.

    Article  Google Scholar 

  34. Black DW, Arndt S, Coryell WH, Argo T, Forbush KT, Shaw MC, et al. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. J Clin Psychopharmacol. 2007;27(2):143–50.

    Article  CAS  Google Scholar 

  35. Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry. 2002;63(7):559–64.

    Article  CAS  Google Scholar 

  36. Hollander E, Pallanti S, Allen A, Sood E, Rossi NB. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry. 2005;162(1):137–45.

    Article  Google Scholar 

  37. Black DW, Shaw MC, Allen J. Extended release carbamazepine in the treatment of pathological gambling: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1191–4.

    Article  CAS  Google Scholar 

  38. McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE Jr. Olanzapine in the, treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry. 2008;69(3):433–40.

    Article  CAS  Google Scholar 

  39. Fong T, Kalechstein A, Bernhard B, Rosenthal R, Rugle L. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav. 2008;89(3):298–303.

    Google Scholar 

  40. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology. 2005;30(1):205–11.

    Article  CAS  Google Scholar 

  41. Zack M, Poulos CX. Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity. J Psychopharmacol. 2008;23(6):660–71.

    Article  Google Scholar 

  42. Blaszczynski A, Nower L. A pathways model of problem and pathological gambling. Addiction. 2002;97(5):487–99.

    Article  Google Scholar 

  43. Ledgerwood DM, Petry NM. Psychological experience of gambling and subtypes of pathological gamblers. Psychiatry Res. 2006;144(1):17–27.

    Article  Google Scholar 

  44. Grant JE, Odlaug BL, Chamberlain SR, Potenza MN, Schreiber LR, Donahue CB, Kim SW. A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psychiatry. 2013;75(1):39–45.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Texas, Southwestern Medical Center, Dallas, TX, USA

    Gustavo C. Medeiros

  2. Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA

    Jon E. Grant

Authors
  1. Gustavo C. Medeiros
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jon E. Grant
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Psychiatry and Psychotherapy, Charité – University Medicine Berlin, Berlin, Germany

    Andreas Heinz

  2. Department of Psychiatry and Psychotherapy, Charité – University Medicine Berlin, Berlin, Germany

    Nina Romanczuk-Seiferth

  3. Department of Psychiatry, Yale University, New Haven, CT, USA

    Marc N. Potenza

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Medeiros, G.C., Grant, J.E. (2019). Pharmacological Interventions in Gambling Disorder. In: Heinz, A., Romanczuk-Seiferth, N., Potenza, M. (eds) Gambling Disorder. Springer, Cham. https://doi.org/10.1007/978-3-030-03060-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-03060-5_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-03058-2

  • Online ISBN: 978-3-030-03060-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation